Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study
Autor/a
Laguno, M.
Von Wichmann, M. A.
Van den Eynde, E.
Navarro, J.
Cifuentes, Carmen
Murillas, J.
Veloso, S.
Martínez-Rebollar, M.
Guardiola, J.M.
Jou, A.
Gómez-Sirvent, J.L.
Cervantes, M.
Pineda, J.A.
López-Calvo, S.
Carrero, Ana
Montes, M.L.
Deig, E.
Tapiz, A.
Ruiz-Mesa, J.D.
Cruceta, A.
de Lazzari, E.
Mallolas, Josep
Fecha de publicación
2016-12ISSN
1201-9712
Resumen
Introduction: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-α2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV–HCV co-infected patients with HCV genotype 1. Methods: This was a phase III prospective trial. HIV–HCV (genotype 1) co-infected patients from 16 hospitals in Spain were included. These patients received 4 weeks of PEG-IFN/RBV (lead-in), followed by response-guided therapy with PEG-IFN/RBV plus BOC (a fixed 44 weeks was indicated in the case of cirrhosis). The primary endpoint was the sustained virological response (SVR) rate at 24 weeks post-treatment. Efficacy and safety were evaluated in all patients who received at least one dose of the study drug. Results: From June 2013 to April 2014, 102 patients were enrolled, 98 of whom received at least one treatment dose. Seventy-three percent were male, 34% were cirrhotic, 23% had IL28b CC, 65% had genotype 1a, and 41% were previous null responders. The overall SVR rate was 67%. Previous null-responders and cirrhotic patients had lower SVR rates (57% and 51%, respectively). Seventy-six patients (78%) completed the therapy scheme; the most common reasons for discontinuation were lack of response at week 12 (12 patients) and adverse events (six patients). Conclusions: Response-guided therapy with BOC in combination with PEG-IFN/RBV led to an overall SVR rate of 67%, but an SVR rate of only 51% in patients with cirrhosis. The therapy was generally well tolerated. Although the current standards of care do not include BOC + PEG-IFN/RBV, the authors believe that this combination can be beneficial in situations where new HCV direct antiviral agent interferon-free therapies are not available yet.
Tipo de documento
Artículo
Versión del documento
Versión publicada
Lengua
English
Materias (CDU)
61 - Medicina
616.9 - Enfermedades infecciosas y contagiosas. Fiebres
Palabras clave
Teràpia PEG-IFN
RBV + BOC
Pacients
VIH-VHC
Genotip 1
Inhibidors orals
Hepatitis C
Boceprevir
Proteasa
Terapia PEG-IFN
RBV + BOC
Pacientes
VIH-VHC
Genotipo 1
Inhibidores orales
Hepatitis C
Boceprevir
Peptidasas
PEG-IFN therapy
RBV + BOC
Patients
VIH-VHC
Genotype 1
Oral inhibitors
Hepatitis C
Boceprevir
Protease
Páginas
6
Publicado por
Elsevier
Colección
53;
Publicado en
International Journal of Infectious Diseases
Citación
Laguno, M.; Von Wichmann, M. A.; Van den Eynde, E. [et al.]. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study. International Journal of Infectious Diseases, 2016, 53, p. 46-51. Disponible en: <https://www.sciencedirect.com/science/article/pii/S1201971216312127?via%3Dihub>. Fecha de acceso: 14 jun. 2021. DOI: 10.1016/j.ijid.2016.10.028
Este ítem aparece en la(s) siguiente(s) colección(ones)
- Ciències de la Salut [738]
Derechos
© 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Excepto si se señala otra cosa, la licencia del ítem se describe como https://creativecommons.org/licenses/by-nc-nd/4.0/